P53-Armed Oncolytic Virotherapy Promotes the Efficacy of PD1 Blockade in Murine Osteosarcoma Tumors
Our results suggest that P53-armed OBP-702 is a promising agent for improving the antitumor effect of PD1 blockade in treating invasive OS.
Authors
- Toshifumi Ozaki (ORCID: https://orcid.org/0000-0003-1732-9307)
- Hiroya Kondo (ORCID: https://orcid.org/0000-0002-4642-5448)
- Tomohiro Fujiwara (ORCID: https://orcid.org/0000-0003-4257-9180)
- Joe Hasei (ORCID: https://orcid.org/0000-0002-4028-0786)
- Koji Demiya
- Koji Uotani (ORCID: https://orcid.org/0000-0002-5594-1292)
- Tadashi Komatsubara (ORCID: https://orcid.org/0009-0005-0270-7071)
- H. Tazawa
- Miho Kure
- Yasuo Urata
- SHUNSUKE KAGAWA
- AKI YOSHIDA
- TOSHIYUKI KUNISADA
- TOSHIYOSHI FUJIWARA
- YUSUKE MOCHIZUKI
Institutions
- Okayama University (JP)
- Okayama University Hospital (JP)
- Oncolys BioPharma (Japan) (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-12-30
- DOI
- https://doi.org/10.21873/anticanres.17924
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science